Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication.
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication. J Immunother Cancer. 2020 06; 8(1).